Brokerages predict that Omnicell, Inc. (NASDAQ:OMCL) will post earnings per share (EPS) of $0.52 for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for Omnicell’s earnings. The lowest EPS estimate is $0.52 and the highest is $0.53. Omnicell reported earnings per share of $0.37 during the same quarter last year, which would suggest a positive year over year growth rate of 40.5%. The company is expected to report its next quarterly earnings report on Wednesday, February 21st.
According to Zacks, analysts expect that Omnicell will report full-year earnings of $1.31 per share for the current financial year, with EPS estimates ranging from $1.30 to $1.32. For the next year, analysts anticipate that the firm will report earnings of $1.96 per share, with EPS estimates ranging from $1.88 to $2.05. Zacks’ earnings per share calculations are an average based on a survey of sell-side research analysts that that provide coverage for Omnicell.
Omnicell (NASDAQ:OMCL) last announced its earnings results on Thursday, October 26th. The company reported $0.42 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $0.42. Omnicell had a negative net margin of 0.51% and a negative return on equity of 0.79%. The firm had revenue of $186.78 million for the quarter, compared to analyst estimates of $192.45 million. During the same quarter last year, the business earned $0.40 earnings per share. Omnicell’s revenue was up 5.7% compared to the same quarter last year.
A number of analysts recently issued reports on the stock. Zacks Investment Research upgraded shares of Omnicell from a “strong sell” rating to a “hold” rating in a research report on Wednesday, December 27th. Cantor Fitzgerald restated a “buy” rating and set a $60.00 target price on shares of Omnicell in a research report on Tuesday, December 5th. BidaskClub lowered shares of Omnicell from a “hold” rating to a “sell” rating in a research report on Friday, December 22nd. Oppenheimer restated a “buy” rating and set a $55.00 target price on shares of Omnicell in a research report on Thursday, October 19th. Finally, Craig Hallum restated a “buy” rating and set a $62.00 target price (up previously from $52.00) on shares of Omnicell in a research report on Monday, October 30th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and six have given a buy rating to the company. Omnicell currently has a consensus rating of “Buy” and an average price target of $55.14.
Shares of Omnicell (NASDAQ OMCL) opened at $50.35 on Friday. Omnicell has a 1 year low of $31.85 and a 1 year high of $55.40. The stock has a market cap of $1,840.00, a P/E ratio of -457.73, a P/E/G ratio of 3.88 and a beta of 0.71. The company has a debt-to-equity ratio of 0.38, a quick ratio of 1.08 and a current ratio of 1.53.
In other Omnicell news, CFO Peter J. Kuipers sold 1,926 shares of the stock in a transaction that occurred on Monday, December 18th. The shares were sold at an average price of $51.69, for a total transaction of $99,554.94. Following the transaction, the chief financial officer now owns 40,544 shares of the company’s stock, valued at $2,095,719.36. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, VP Jorge R. Taborga sold 6,295 shares of the stock in a transaction that occurred on Monday, November 6th. The stock was sold at an average price of $48.69, for a total transaction of $306,503.55. Following the transaction, the vice president now directly owns 50,013 shares in the company, valued at approximately $2,435,132.97. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 27,558 shares of company stock worth $1,330,230. 3.77% of the stock is currently owned by insiders.
A number of large investors have recently bought and sold shares of the business. BlackRock Inc. raised its stake in Omnicell by 2.3% during the second quarter. BlackRock Inc. now owns 4,589,119 shares of the company’s stock worth $197,790,000 after purchasing an additional 101,776 shares during the period. Vanguard Group Inc. raised its stake in Omnicell by 3.7% during the second quarter. Vanguard Group Inc. now owns 1,928,201 shares of the company’s stock worth $83,105,000 after purchasing an additional 67,902 shares during the period. Conestoga Capital Advisors LLC raised its stake in Omnicell by 0.7% during the third quarter. Conestoga Capital Advisors LLC now owns 1,617,706 shares of the company’s stock worth $82,584,000 after purchasing an additional 11,105 shares during the period. Oak Ridge Investments LLC raised its stake in Omnicell by 0.6% during the second quarter. Oak Ridge Investments LLC now owns 1,537,940 shares of the company’s stock worth $66,285,000 after purchasing an additional 8,491 shares during the period. Finally, Janus Henderson Group PLC raised its stake in Omnicell by 129.6% during the second quarter. Janus Henderson Group PLC now owns 1,231,933 shares of the company’s stock worth $53,096,000 after purchasing an additional 695,334 shares during the period. 99.61% of the stock is currently owned by institutional investors.
COPYRIGHT VIOLATION NOTICE: “Brokerages Anticipate Omnicell, Inc. (OMCL) Will Announce Earnings of $0.52 Per Share” was published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this piece of content can be viewed at https://ledgergazette.com/2018/01/06/brokerages-anticipate-omnicell-inc-omcl-will-announce-earnings-of-0-52-per-share.html.
Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.